Multimodal functional imaging for early response assessment in GIST patients treated with imatinib
نویسندگان
چکیده
1 Department of Radiology and Nuclear Medicine, Oslo University Hospital, Nydalen, Oslo, Norway; 2 Institute for Clinical Medicine, University of Oslo, Blindern, Oslo, Norway; 3 Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Nydalen, Oslo, Norway; 4 Department of Pathology, Oslo University Hospital, The Norwegian Radium Hospital, Nydalen, Oslo, Norway and 5 Faculty of Health Sciences, Buskerud University College, Drammen, Norway
منابع مشابه
The potential value of F-18 FDG PET in comparison to ct in early prediction of response to Imatinib (STI571) therapy in patients with gastrointestinal stromal tumors
Introduction: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. GIST has been shown to over-express c-KIT (CD117), the receptor tyrosine kinase. Imatinib (STI571 or Glivec) is a new type of tyrosine kinase inhibitor that selectively inhibits various tyrosine kinases and has been successfully used to trea...
متن کامل18F-FDG PET Imaging in the Evaluation of Treatment Response to New Chemotherapies beyond Imatinib for Patients with Gastrointestinal Stromal Tumors
Aim. (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) is a powerful tool for staging and defining "good responders" to chemotherapy in tumor setting. Gastrointestinal stromal tumors (GISTs) are sarcoma involving gastrointestinal tract and may require a chemotherapy including imatinib, a tyrosine kinase inhibitor agent. Some GIST patients become refractory to imatinib; there...
متن کاملMicrosoft Word - 34-42 Eng
Introduction: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. GIST has been shown to over-express c-KIT (CD117), the receptor tyrosine kinase. Imatinib (STI571 or Glivec) is a new type of tyrosine kinase inhibitor that selectively inhibits various tyrosine kinases and has been successfully used to treat GIST. In this study we have...
متن کاملControversies in the surgical management of GIST in the era of imatinib.
Because of its relatively low toxicity and significant efficacy in the treatment of GIST, imatinib has dramatically altered the natural history of this disease. Early studies, however, have not adequately addressed the optimal length and dose of adjuvant and neoadjuvant imatinib therapy, defined the subset of candidates most likely to benefit from such therapy, determined the long-term impact o...
متن کاملTwo cases of complete response after imatinib mesylate treatment of advanced GIST.
BACKGROUND Imatinib mesylate has undoubted efficacy in the treatment of advanced gastrointestinal stromal tumors (GISTs), but complete responses have only been reported rarely. CASE REPORT A 47-year-old man with liver metastasis from GIST achieved a complete response after 7 months of treatment with imatinib and a 47-year old woman with local relapse of GIST on the stomach after gastrectomy, ...
متن کامل